Sort   by:  
 Page size 
UnknownTwo Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
Not available
S-EPMC8189692 | biostudies-literature
UnknownCross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants.
Not available
S-EPMC10249892 | biostudies-literature
UnknownDistinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants.
Not available
S-EPMC12674122 | biostudies-literature
UnknownPhase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.
Not available
S-EPMC3485893 | biostudies-literature
UnknownImpact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature.
Not available
S-EPMC7398916 | biostudies-literature
UnknownDaily Vaginal Swabs and Mobile Phone Sex Report for Assessing HIV Virion Exposure Prospectively Among a Cohort of Young Sexually Active Women in South Africa (HVTN 915).
Not available
S-EPMC6743720 | biostudies-literature
UnknownDevelopment of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulation.
Not available
S-EPMC9087172 | biostudies-literature
UnknownPoststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees.
Not available
S-EPMC7813203 | biostudies-literature
UnknownA trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.
Not available
S-EPMC3068023 | biostudies-literature
UnknownSafety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.
Not available
S-EPMC3252307 | biostudies-literature
Sort   by:  
 Page size